Galimedix’s GAL-101 is intended to treat glaucoma and dry age-related macular degeneration. Credit: Amanda Dalbjörn on Unsplash.

Laboratoires Théa’s sister company, Théa Open Innovation (TOI), has signed a licensing agreement with Galimedix Therapeutics for GAL-101.

Under the agreement’s terms, TOI will receive exclusive rights to develop and commercialise Galimedix Therapeutics’ disease-modifying compound, GAL-101.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GAL-101 binds to a specific motif from Aβ that is exposed only in the misfolded Aβ monomer form and can be targeted.

The topical and oral form of the compound is intended to treat glaucoma and dry age-related macular degeneration (AMD), as well as other ophthalmic indications with high unmet medical need, in Africa, the Middle East, the Americas and Europe.

It is currently ready to enter Phase II/III clinical trials.

See Also:

Under the terms of the deal, TOI will pay an upfront technology access fee to Galimedix, which is also eligible for further success-based milestone payments along with royalties on net sales.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company will completely fund GAL-101’s remaining development in dry AMD and will also be responsible for the registration and commercialisation of the drug, while Galimedix will handle the mid-stage clinical trials.

Théa Group president Jean-Frédéric Chibret said: “Through the partnership with Galimedix, Thea will be among the few companies globally which are working on an innovative drug for the treatment of dry AMD patients who are currently at risk of going blind.

“We are excited to be working with Galimedix, as this collaboration supports our continued commitment to building a strong, cutting-edge and diversified ophthalmological portfolio for eye care specialists around the world and their patients.”